14 terminated. 14 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Terminated 14 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Eczema: new trials by email Literature Review of Eczema trials Research Report on Eczema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. GSK1070806, Placebo - Dermatitis, Atopic | Phase 2 | Terminated | GlaxoSmithKline | 79 | 2024-06-05 | 2026-06-16 |
| A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis GSK1070806, Placebo - Dermatitis, Atopic | Phase 2 | Terminated | GlaxoSmithKline | 161 | 2023-11-16 | 2026-06-03 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) Placebo, IMG-007 - Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | Phase 1 / Phase 2 | Terminated | Inmagene LLC | 13 | 2023-08-09 | 2025-11-06 |
| A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection etrasimod, Placebo - Atopic Dermatitis, Atopic Dermatitis, Unspecified | Phase 2 / Phase 3 | Terminated | Pfizer | 58 | 2023-01-18 | 2025-05-08 |
| A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis AK002, Placebo - Atopic Dermatitis | Phase 2 | Terminated | Allakos Inc. | 131 | 2022-06-27 | 2024-10-15 |
| A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials EDP1815 - Atopic Dermatitis | Phase 2 | Terminated | Evelo Biosciences, Inc. | 287 | 2022-06-06 | 2023-09-07 |
| Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study FB-401 - Atopic Dermatitis | Phase 2 | Terminated | Forte Biosciences, Inc. | 36 | 2021-06-02 | 2021-10-28 |
| Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer Mepitel Film® - Breast Cancer, Radiotherapy; Adverse Effect, Dermatitis or Eczema | Phase 2 | Terminated | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 40 | 2020-01-15 | 2023-11-08 |
| A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients ZPL389 30mg, ZPL389 50mg, TCS and/or TCI - Atopic Dermatitis | Phase 2 | Terminated | Novartis Pharmaceuticals | 123 | 2019-04-04 | 2021-10-08 |
| A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis Tezepelumab, Placebo - Atopic Dermatitis | Phase 2 | Terminated | Amgen | 251 | 2019-03-15 | 2022-03-10 |
| A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis LY3375880, Placebo - Atopic Dermatitis | Phase 2 | Terminated | Eli Lilly and Company | 136 | 2019-02-12 | 2021-04-20 |
| A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis Placebo, ZPL389 3mg, ZPL389 10mg - Atopic Dermatitis | Phase 2 | Terminated | Novartis Pharmaceuticals | 293 | 2018-11-14 | 2021-10-08 |
| Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis ASN002 - Atopic Dermatitis | Phase 2 | Terminated | Asana BioSciences | 162 | 2018-09-29 | 2023-09-18 |
| Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis Neuroskin Forte, Placebo Application - Psoriasis, Eczema | Phase 2 | Terminated | University of Medicine and Dentistry of New Jersey | 13 | 2005-09-01 | 2017-04-25 |
Dermatitis, Atopic (13) · Dermatitis (8) · Immune System Diseases (4) · Skin Diseases (3) · Pruritus (2) · Breast Neoplasms (1) · Inflammation (1) · Psoriasis (1) · Radiation Injuries (1) · Radiodermatitis (1) · Skin Diseases, Eczematous (1)
Skin and Connective Tissue Diseases (14) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (13) · Genetic Diseases, Inborn (13) · Hypersensitivity (13) · Hypersensitivity, Immediate (13) · Skin Diseases, Eczematous (13) · Skin Diseases, Genetic (13) · Skin Diseases (11) · Immune System Diseases (9) · Dermatitis (6) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (2) · Skin Manifestations (2) · Breast Diseases (1) · Neoplasms (1)
GSK1070806 (2) · AK002 (1) · etrasimod (1) · gusacitinib (1) · tezepelumab (1)
GlaxoSmithKline (2) · Novartis Pharmaceuticals (2) · Allakos Inc. (1) · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (1) · Amgen (1) · Asana BioSciences (1) · Eli Lilly and Company (1) · Evelo Biosciences, Inc. (1) · Forte Biosciences, Inc. (1) · Inmagene LLC (1) · Pfizer (1) · University of Medicine and Dentistry of New Jersey (1)
United States (13) · Canada (10) · Germany (8) · Poland (7) · Czechia (6) · Japan (6) · Spain (4) · Argentina (3) · Bulgaria (3) · France (3) · Hungary (3) · Mexico (3) · South Korea (3) · United Kingdom (3) · Australia (2)
Ben Ehst, PhD (1) · Chin Lee, MD, MPH (1) · David Zammit, Ph.D. (1) · Douglas Maslin, MD (1) · Mark Trombetta, MD (1) · Melissa Magliocco, MD (1)
2018 (3), 2023 (2)